GDRX · GoodRx Holdings, Inc. · Documents

Aug 8

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $200.61M ▲ 5.8% Net income $6.69M ▼ 88.6% Diluted EPS $0.02 ▼ 85.7%

Jul 11

Current report 8-K Events of Jul 10

Entered into a material agreement, New debt or off-balance-sheet obligation

Jul 10

Current report 8-K Events of Jul 8

Director or officer change, or executive pay, Regulation FD disclosure

Jun 7

Current report 8-K Events of Jun 6

Shareholder vote results

May 30

Current report 8-K Events of May 29

Director or officer change, or executive pay, Regulation FD disclosure

May 30

Proxy statement DEFA14A

Proxy statement

May 9

Earnings call

Q1 2024 earnings call

May 9

Current report 8-K

Financial results

May 9

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $197.88M ▲ 7.6% Net loss $1.01M Diluted EPS $0.00

Apr 25

Proxy statement DEF 14A

Proxy statement

Apr 25

Annual report to holders ARS

Annual report to holders

Apr 25

Proxy statement DEFA14A

Proxy statement

Apr 5

Registration statement S-3

Registration statement

Mar 14

Current report 8-K Events of Mar 13

Director or officer change, or executive pay, Regulation FD disclosure

Mar 7

Current report 8-K Events of Mar 6

Other events

Mar 7

Current report 8-K

Director or officer change, or executive pay

Feb 29

Earnings call

Q4 2023 earnings call

Feb 29

Current report 8-K

Financial results

Feb 29

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $750.27M ▼ 2.1% Net loss $8.87M Diluted EPS -$0.02

Feb 26

Current report 8-K Events of Feb 23

Entered into a material agreement, New debt or off-balance-sheet obligation, Director or officer change, or executive pay

Jan 17

Current report 8-K Events of Jan 16

Director or officer change, or executive pay

Jan 10

Current report 8-K

Financial results

Dec 22

Current report 8-K Events of Dec 21

Director or officer change, or executive pay, Regulation FD disclosure

Dec 5

Current report 8-K

Regulation FD disclosure

Nov 21

Current report 8-K Events of Nov 20

Other events

Nov 9

Earnings call

Q3 2023 earnings call

Nov 9

Current report 8-K

Financial results

Nov 9

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $179.96M ▼ 3.9% Net loss $38.5M Diluted EPS -$0.09

Aug 9

Earnings call

Q2 2023 earnings call

Aug 9

Current report 8-K

Financial results

Aug 9

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $189.68M ▼ 1.1% Net income $58.79M Diluted EPS $0.14

Jul 27

Current report 8-K Events of Jul 26

Director or officer change, or executive pay

Jun 27

Current report 8-K

Director or officer change, or executive pay

Jun 16

Current report 8-K Events of Jun 14

Shareholder vote results

Jun 6

Current report 8-K Events of Jun 5

Delisting notice or listing transfer, Director or officer change, or executive pay

Jun 6

Proxy statement DEFA14A

Proxy statement

Jun 2

Current report 8-K Events of May 30

Director or officer change, or executive pay

May 10

Current report 8-K

Financial results

May 10

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $183.99M ▼ 9.5% Net loss $3.29M Diluted EPS -$0.01

May 1

Proxy statement DEF 14A

Proxy statement

May 1

Annual report to holders ARS

Annual report to holders

May 1

Proxy statement DEFA14A

Proxy statement

Apr 25

Earnings call

Q1 2023 earnings call

Apr 25

Current report 8-K

Financial results, Director or officer change, or executive pay

Mar 13

Current report 8-K

Regulation FD disclosure

Mar 1

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $766.55M ▲ 2.8% Net loss $32.83M Diluted EPS -$0.08

Feb 28

Earnings call

Q4 2022 earnings call

Feb 28

Current report 8-K

Financial results

Dec 9

Current report 8-K

Other events

Nov 10

Current report 8-K

Other events